Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
September 21, 2021
Assignee:
Umecrine Cognition AB
Inventors:
Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
Type:
Grant
Filed:
June 24, 2019
Date of Patent:
March 31, 2020
Assignee:
Umecrine Cognition AB
Inventors:
Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime, represented by the following structural formula: or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.
Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
July 9, 2019
Assignee:
Umecrine Cognition AB
Inventors:
Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
May 7, 2019
Assignee:
Umecrine Cognition AB
Inventors:
Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.
Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
Type:
Grant
Filed:
November 15, 2016
Date of Patent:
October 31, 2017
Assignee:
Umecrine Cognition AB
Inventors:
Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Type:
Application
Filed:
January 7, 2011
Publication date:
April 28, 2011
Applicant:
UMECRINE COGNITION AB
Inventors:
Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson